A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

NCT06649448 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor Cancer
Chemotherapy Induced Neutropenia
G-CSF

Interventions

DRUG: Efbemalenograstim alfa Injection
DRUG: carboplatin/cisplatin-etoposide
DRUG: Carboplatin plus Paclitaxel
DRUG: Cisplatin/pemetrexed or Carboplatin/pemetrexed
DRUG: TP regimen

Sponsor

Shandong Cancer Hospital and Institute